Hepatobiliary disease is any condition that damages or disrupts the liver, gallbladder, or bile ducts, the interconnected organs responsible for producing, storing, and transporting bile to digest fats and filter toxins from the blood. The term covers an enormous range of problems, from gallstones and fatty liver disease to viral hepatitis, autoimmune conditions, and cancers. Treatment depends entirely on which part of the system is affected and how far the disease has progressed, ranging from lifestyle changes and medications to endoscopic procedures and organ transplantation.
What the Hepatobiliary System Actually Does
The liver, gallbladder, and bile ducts work as a single functional unit. The liver produces bile, a yellow-green fluid loaded with bile salts that help break down dietary fats in the small intestine. Bile travels from the liver through a branching network of small and large ducts, gets stored and concentrated in the gallbladder, and is released into the intestine after you eat. The liver also processes nutrients absorbed from the gut, metabolizes drugs and alcohol, produces clotting factors, and filters bacterial products that arrive via the portal vein from the intestines. When any part of this chain breaks down, the consequences ripple outward: fat digestion suffers, toxins accumulate, and inflammation can spiral into scarring and organ failure.
Fatty Liver Disease and the Metabolic Spectrum
The most common hepatobiliary condition in wealthy countries is now metabolic dysfunction-associated steatotic liver disease, or MASLD (previously called non-alcoholic fatty liver disease). In MASLD, fat accumulates inside liver cells, driven primarily by excess calorie intake, insulin resistance, and obesity. For many people, fatty liver causes no symptoms and stays relatively harmless. But in a meaningful fraction of cases, it progresses to metabolic dysfunction-associated steatohepatitis (MASH), where fat buildup triggers inflammation and progressive scarring. MASH can advance to cirrhosis, liver cancer, and liver failure, making it a serious public health concern worldwide.1PubMed Central. Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease-the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression
Research into the molecular drivers of this progression is active. For example, a small RNA molecule called miR-33 has been found at elevated levels in the livers of both humans and mice with MASLD. In animal studies, deleting miR-33 in liver cells improved fat accumulation and inflammation and slowed the progression toward MASH, fibrosis, and liver cancer.2PubMed Central. miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression This kind of finding does not translate directly into a treatment you can take today, but it illustrates how researchers are trying to identify intervention points that could stop fatty liver disease before it reaches the irreversible stages.
Viral Hepatitis
Hepatitis B and hepatitis C remain leading infectious causes of hepatobiliary disease globally. Chronic hepatitis B alone affects more than 250 million people worldwide, and ongoing infection drives progressive liver inflammation that can lead to cirrhosis and hepatocellular carcinoma, the most common form of primary liver cancer.3Europe PMC. Hepatitis B virus-induced cirrhosis: Mechanisms, global variations, and treatment advances The virus does not directly kill liver cells in most cases; instead, the immune system’s attempt to clear infected cells causes ongoing damage, and the virus itself can integrate into liver-cell DNA, promoting cancerous changes over decades.
Not all hepatitis B infections carry the same risk. The virus comes in several genotypes, and genotype C, which is common in East and Southeast Asia, has been linked to more persistent viral replication, more active liver inflammation, and a higher risk of liver cancer. Specific mutations in the viral genome appear to reshape how the virus interacts with the immune system and drive cancer-promoting signals in liver cells.4PMC. Molecular Basis and Clinical Significance of the High-risk Phenotype of Hepatitis B Virus Genotype C This matters practically because it helps explain why two people with chronic hepatitis B can have very different outcomes and why antiviral treatment decisions sometimes account for which genotype a patient carries.
Hepatitis C, meanwhile, has been revolutionized by direct-acting antiviral drugs that cure infection in the vast majority of patients within a few months. But cure does not erase all consequences. Patients who already have significant fibrosis or cirrhosis at the time of treatment still need ongoing monitoring for liver cancer, and occasionally, viral clearance unmasks or triggers other immune-mediated liver conditions. At least two case reports have documented the onset of primary biliary cholangitis after hepatitis C was eradicated with direct-acting antivirals, suggesting that the immune reshuffling after viral clearance can sometimes redirect the attack toward bile ducts.5European Review for Medical and Pharmacological Sciences. Primary biliary cholangitis development after hepatitis C virus eradication with direct acting antivirals: a case report and review of the literature
Autoimmune and Biliary Disorders
Some hepatobiliary diseases arise when the immune system attacks the liver’s own tissue. Primary biliary cholangitis (PBC) is a chronic autoimmune condition in which immune cells gradually destroy the small bile ducts inside the liver, causing bile to back up and damage surrounding liver tissue. PBC predominantly affects women and is thought to be triggered by environmental factors in people who are genetically susceptible. A hallmark of the disease is the presence of antimitochondrial antibodies (AMAs), which are found in roughly 90 to 95 percent of PBC patients and in fewer than one percent of healthy people, making them a highly specific diagnostic marker.6PubMed Central. Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women’s Health Perspective
Primary sclerosing cholangitis (PSC) is a related but distinct condition in which both the small and large bile ducts become inflamed and scarred, leading to strictures that block bile flow. PSC has a strong association with inflammatory bowel disease, especially ulcerative colitis. Unlike PBC, PSC lacks a single reliable blood marker, and diagnosis often depends on imaging that reveals the characteristic “beaded” pattern of alternating narrowing and dilation in the bile ducts. MR elastography, which measures liver stiffness, has been studied as a monitoring tool in PSC and shows significant correlations between stiffness and the presence of bile duct strictures, as well as signs of advanced disease like enlarged spleen and varices.7SpringerLink. MR elastography in primary sclerosing cholangitis: correlating liver stiffness with bile duct strictures and parenchymal changes
Gallstones and Gallbladder Disease
Gallstones are among the most common hepatobiliary problems, and they disproportionately affect women. Stones form when the chemical balance of bile shifts, allowing cholesterol or bilirubin to crystallize. The process is not purely chemical: certain bacteria in the gallbladder actively participate in stone formation by altering bile composition and producing enzymes that promote crystallization. These bacterial contributions help explain why gallstones sometimes recur even after risk factors like diet and weight have been addressed.8SpringerLink. The role of bacteria in gallstone formation Complications range from biliary colic, the intense pain that occurs when a stone temporarily blocks a duct, to cholecystitis (gallbladder inflammation), infection, and in rare chronic cases, gallbladder cancer.
Bacterial products also play a role in a more recently described mechanism of stone formation. Lipopolysaccharide, a component of certain bacteria, can damage the protective mucosal barrier of the gallbladder and trigger an immune response that promotes the formation of web-like structures from immune cells called neutrophil extracellular traps. These traps act as scaffolding that accelerates stone aggregation.9Dove Press. Lipopolysaccharide in Bile Promotes the Neutrophil Extracellular Traps-Induced Gallstone Formation by Activating the Gallbladder Immune Barrier Gallbladder removal (cholecystectomy) is the standard definitive treatment for symptomatic gallstones and is one of the most frequently performed surgeries worldwide.
Drug-Induced Liver Injury
The liver processes nearly every drug you take, and that work sometimes causes direct harm. Drug-induced liver injury (DILI) comes in two broad forms. The first is predictable and dose-dependent, with acetaminophen (paracetamol) as the classic example: take enough of it and it will damage your liver, full stop.10Europe PMC. Mechanisms of drug-induced liver injury The second form, idiosyncratic DILI, is unpredictable and occurs at normal doses in a small number of people whose genetic makeup and environment make them unusually vulnerable.
Growing evidence suggests that most idiosyncratic drug reactions in the liver are immune-mediated. When the liver breaks down a drug, some of the resulting reactive molecules can bind to proteins and make them look foreign to the immune system. If those reactive molecules also cause enough cell damage to release distress signals, the immune system may mount a full attack on liver tissue rather than tolerating the altered proteins.11Academic Press / Elsevier via PubMed Central. Mechanisms of idiosyncratic drug-induced liver injury This is why idiosyncratic DILI is so hard to predict: it requires an unlucky combination of the drug’s chemistry, the individual’s metabolic quirks, and enough concurrent cell stress to tip the immune response from tolerance to attack. Hundreds of medications, herbal supplements, and dietary products have been implicated, and DILI remains a leading reason drugs get pulled from the market after approval.
How Hepatobiliary Disease Is Diagnosed
Diagnosis usually begins with blood tests that measure liver enzymes. The enzymes ALT and AST leak from damaged liver cells into the bloodstream, so elevated levels indicate that hepatocytes are being injured. ALP (alkaline phosphatase) and GGT rise when bile flow is obstructed. Together, these markers help doctors distinguish between a hepatocellular pattern of injury (mainly ALT and AST elevation, suggesting liver-cell damage) and a cholestatic pattern (mainly ALP elevation, suggesting bile duct obstruction or disease).12CrossRef. Liver enzyme alterations in hepatic diseases: Clinical insights into ALT, AST, and ALP Variations
Imaging comes next. Ultrasound is the first-line tool for spotting gallstones, duct dilation, and obvious liver lesions. CT scans and MRI provide more detail, and specialized techniques like MR elastography can assess liver stiffness as a proxy for fibrosis without requiring a biopsy. For bile duct diseases specifically, magnetic resonance cholangiopancreatography (MRCP) gives a detailed map of the duct system. When tissue is needed for a definitive answer, liver biopsy remains the gold standard, though its use has decreased as non-invasive alternatives have improved. Autoimmune conditions bring their own blood markers into play: antimitochondrial antibodies for PBC, as mentioned earlier, and various other autoantibodies for autoimmune hepatitis.
Medical Treatments
Treatment strategies vary enormously depending on the specific disease. For autoimmune conditions like PBC, ursodeoxycholic acid (UDCA), a synthetic bile acid, has been the backbone of therapy for decades. It works by replacing toxic bile acids with a less harmful version, reducing bile duct damage and slowing disease progression. For autoimmune hepatitis, corticosteroids and immunosuppressants are used to dampen the immune attack on liver cells.
For fatty liver disease, the treatment landscape has recently shifted in an important way. In 2024, resmetirom became the first drug approved specifically for MASH with moderate to advanced fibrosis. It works by activating thyroid hormone receptors in the liver to boost fat metabolism, effectively reducing fat accumulation and liver scarring without triggering the systemic effects of thyroid hormones throughout the body. Clinical trials showed that resmetirom resolved MASH without worsening fibrosis and had a favorable safety profile.13Europe PMC. Resmetirom: The First Disease-Specific Treatment for MASH Alongside resmetirom, GLP-1 receptor agonists like semaglutide, originally developed for diabetes and weight loss, have shown high rates of MASH resolution and provide substantial weight loss and cardiovascular risk reduction, though they appear to have more limited direct effects on liver fibrosis compared to resmetirom.14Exploration of Drug Science. Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective The two drugs target different aspects of the disease, and researchers are already exploring whether combining them could address both the metabolic and fibrotic components simultaneously.
Antiviral therapy for chronic hepatitis B typically uses nucleos(t)ide analogues that suppress viral replication, reducing liver inflammation and lowering the risk of cirrhosis and cancer over time. These drugs usually need to be taken long-term because they rarely eliminate the virus entirely. For hepatitis C, the direct-acting antivirals mentioned earlier achieve cure rates above 95 percent in most populations.
Surgical and Endoscopic Procedures
When medications are not enough, several procedural options exist. Endoscopic retrograde cholangiopancreatography (ERCP) has become a central tool for managing bile duct problems. The most common use is removing stones from the common bile duct during episodes of acute cholangitis, but ERCP is also used to place stents in narrowed ducts and to investigate suspicious strictures that could be cancerous.15Gut and Liver. Biliary Stent Placement by Endoscopic Retrograde Cholangiopancreatography: Quality Indicators and Technical Applications
Cholangioscopy has expanded what ERCP can accomplish. By threading a tiny camera directly into the bile ducts, doctors can visually inspect duct walls, take targeted tissue samples from suspicious areas, and use laser or electrohydraulic lithotripsy to break apart stones that resist conventional extraction.16Frontiers in Medicine. Cholangioscopy-guided ERCP: expanding diagnostic and therapeutic applications For patients whose bile duct stones have been removed, placing a temporary biliary stent after the procedure appears to reduce the risk of stone recurrence. In one study of nearly 500 patients, stones came back in about 8 percent of those who received stents compared to roughly 16 percent of those who did not.17PubMed Central. Effect of stent placement on stone recurrence and post-procedural cholangitis after endoscopic removal of common bile duct stones
For liver cancers that cannot be surgically removed, transarterial chemoembolization (TACE) delivers chemotherapy directly to the tumor through the hepatic artery while blocking the blood supply that feeds it. TACE is effective but not without risk. In rare cases, the procedure can damage bile ducts by cutting off their blood supply, leading to bile duct necrosis that may require surgical repair if conservative management fails.18Elsevier / Int J Surg Case Rep. Common hepatic duct necrosis following transarterial chemoembolization for hepatocellular carcinoma: A case report and literature review
When Hepatobiliary Disease Reaches End Stage
Advanced liver scarring from any cause can lead to cirrhosis, which fundamentally changes how blood flows through the organ. As scar tissue replaces healthy liver tissue, resistance to blood flow through the portal vein increases, a condition called portal hypertension. Portal hypertension drives the most dangerous complications of end-stage liver disease: varices (swollen veins that can rupture and bleed, especially in the esophagus and stomach), ascites (fluid buildup in the abdomen), and hepatic encephalopathy (confusion and altered consciousness from toxins the failing liver can no longer clear).19ScienceDirect. Portal hypertension and ascites
When liver function deteriorates beyond the point of medical management, transplantation becomes the only definitive treatment. In the United States, liver allocation is based on the Model for End-Stage Liver Disease (MELD) score, which estimates short-term mortality risk using laboratory values. Higher MELD scores get priority for available organs. Factors associated with worse five-year survival after transplant include older recipient age, higher MELD score at the time of transplant, older donor age, hepatitis C, hepatocellular carcinoma, need for dialysis, and poor physical function before surgery.20PubMed Central. Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) era
The MELD system works reasonably well for most liver diseases, but there is a mismatch for end-stage biliary diseases. Patients with conditions like PSC or biliary atresia tend to have lower MELD scores than patients with end-stage liver disease from other causes, even when they are equally sick. A comparative study found that MELD score was the only significant factor predicting shorter survival in end-stage biliary disease patients, but that the scoring system did not adequately reflect their clinical severity or need for transplant, raising questions about whether these patients are disadvantaged by the current allocation system.21Baishideng Publishing Group. Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease
Biliary Atresia in Newborns
One hepatobiliary disease that deserves its own mention is biliary atresia, a rare condition in newborns where the bile ducts are absent or blocked, causing severe bile backup that quickly leads to liver damage. The cause remains unknown. If untreated, biliary atresia progresses to biliary cirrhosis and death in the first years of life. Treatment follows a two-step sequence: first, a Kasai procedure (hepatoportoenterostomy), performed in the first months of life, surgically reroutes bile flow to the intestine and tries to slow further liver damage. If the Kasai procedure fails or the disease continues to advance, liver transplantation becomes necessary. Biliary atresia is the most frequent reason for pediatric liver transplantation.22Europe PMC. Biliary atresia: 50 years after the first kasai
Timing is critical. The Kasai procedure is most successful when performed before about 60 days of age, which means early detection of jaundice in newborns matters enormously. A baby who is still jaundiced at two weeks of age (or whose stool is pale and clay-colored) should be evaluated promptly, because the window for effective surgical intervention is narrow.
The Gut-Liver Axis
A growing area of research in hepatobiliary disease involves the two-way relationship between the gut and the liver, sometimes called the gut-liver axis. The liver receives about 70 percent of its blood supply from the portal vein, which drains directly from the intestines. This means the liver is the first organ to encounter whatever the gut absorbs or leaks, including bacterial products. Intestinal bacteria and their metabolic byproducts can contribute to liver disease through several pathways: increased intestinal permeability (a “leaky gut”), chronic low-grade inflammation, altered metabolism, and changes in the production of short-chain fatty acids.23Europe PMC. The role of the gut microbiome in chronic liver disease: the clinical evidence revised
Disruptions to the gut microbiome, the community of bacteria living in the intestine, have been documented across nearly every form of chronic liver disease, from fatty liver disease and alcoholic hepatitis to cirrhosis and PSC. Harmful shifts in microbial composition and their damaging byproducts appear to be a shared feature, worsening intestinal barrier function and feeding into a cycle of liver inflammation.24Microorganisms. Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases This has practical implications: therapies aimed at restoring a healthier gut microbiome, whether through diet, probiotics, or antibiotics like rifaximin (already used to prevent hepatic encephalopathy in cirrhosis), represent a complementary treatment strategy that targets the disease from the intestinal side rather than the liver side.
The Liver’s Capacity to Regenerate
One of the more remarkable features of the hepatobiliary system is the liver’s ability to regrow after injury. Unlike most organs, the liver can restore its original mass even after losing a substantial portion. This is not true regeneration in the way a salamander regrows a limb; instead, the remaining healthy liver cells (hepatocytes) enlarge and divide to compensate for what was lost. Resident stem cells in the liver play only a minor or negligible role in this process under most circumstances.25Europe PMC. Cellular Mechanisms of Liver Regeneration and Cell-Based Therapies of Liver Diseases After acute injuries, this compensatory replication of healthy hepatocytes is usually sufficient to restore liver function.26PubMed Central. Liver regeneration after injury: Mechanisms, cellular interactions and therapeutic innovations
This regenerative ability is what makes living-donor liver transplantation possible: a healthy person donates a portion of their liver, and both the donor’s remaining liver and the transplanted portion grow back toward full size within weeks to months. It also explains why the liver can tolerate significant surgical resection for tumors. But regeneration has limits. In chronic diseases where the injury never stops, such as ongoing alcohol abuse or untreated viral hepatitis, the liver’s attempts at repair get hijacked: repeated cycles of damage and healing lay down scar tissue instead of functional liver cells, eventually producing the irreversible fibrosis of cirrhosis. At that point, the very process that was meant to save the organ becomes part of what destroys it.